We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
Published online by Cambridge University Press: 13 May 2010
ABSTRACT
There has been continuous progress in neurotherapeutics and neuropsychopharmacology in the past year. Notable are the reports of successful preliminary disease-modifying trials in Niemann-Pick disease and Friedreich's ataxia. Progress also has been made in treatment of migraine, stroke, epilepsy, multiple sclerosis, traumatic brain injury, and pain. Biomarkers are increasingly used to establish proof of pharmacology including measures of cerebrospinal fluid constituents and brain changes on magnetic resonance imaging. There is an increasing diversity of patient populations participating in clinical trials, including pediatric migraine and traumatic brain injury.
Key words: argatroban, atorvastatin, biomarkers, bipolar depression, clinical trials, deep brain stimulation, depression, disease modification, duloxatine, epilepsy, fingolimod, Friedreich's ataxia, glatiramer acetate, Huntington's disease, Idebenone, methylphenidate, Miglustat, migraine, modafinil, multiple sclerosis, neuropathic pain, nicardipine, Niemann-Pick Type C disease, Parkinson's disease, pharmacogenetics, pregabalin, retigabin, riluzole, ritogitine, rivastigmine, rizatripan, schizophrenia, spinal cord injury pain, testosterone, tramiprosate, transcranial magnetic stimulation, traumatic brain injury, zolmitriptan, zonisamide.
Progress in Neurotherapeutics and Neuropsychopharmacology 2008
Neurologic and psychiatric disorders are among the most common afflictions of human kind and continue to produce enormous disability globally. It is incumbent on the scientific community to search for means to relieve of neurologic and psychiatric disorders, to improve understanding of disease mechanisms, and to enhance neuropsychopharmacology. There continue to be advances in neurotherapeutics based on an improved understanding of disease mechanisms and improved access to tractable therapeutic targets. Progress in neurotherapeutics in neuropsychopharmacology 2008 captures some of the recent advances in the treatment of neurologic and psychiatric illnesses.
To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Find out more about the Kindle Personal Document Service.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.
